Nitric oxide-sensitive guanylyl cyclase is the only nitric oxide receptor mediating platelet inhibition

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 6, 2010, Pages 1343-1352

  Dangel, O ^a   Mergia, E ^a   Karlisch, K ^a   Groneberg, D ^a,b   Koesling, D ^a   Friebe, A ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Guanylyl cyclase; Hemostasis; Knock out mice; Nitric oxide; Platelets

Indexed keywords

ADENOSINE DIPHOSPHATE; CYCLIC AMP; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; NITRIC OXIDE RECEPTOR; NITRIC OXIDE SENSITIVE GUANYLYLCYCLASE; OXIDE; PHOSPHODIESTERASE III; THROMBIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLEEDING TIME; CALCIUM MOBILIZATION; CALCIUM TRANSPORT; CONTROLLED STUDY; EXOCYTOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ANIMALS; BLOOD PLATELETS; CELL ADHESION; CYCLIC GMP; EXOCYTOSIS; GUANYLATE CYCLASE; MICE; MICE, KNOCKOUT; NITRIC OXIDE; PHOSPHORYLATION; PLATELET AGGREGATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 77954490705     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03806.x     Document Type: Article

References (37)

1. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002, 8:1227-34.
2. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3', 5'-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981, 57:946-55.
3. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987b, 92:181-7.
4. Radomski MW, Palmer RM, Moncada S. Endogenous nitric-oxide inhibits human-platelet adhesion to vascular endothelium. Lancet 1987a, 2:1057-8.
5. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987, 39:163-96.
6. Garthwaite J, Boulton CL. Nitric oxide signalling in the central nervous system. Annu Rev Physiol 1995, 57:683-706.
7. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002, 53:503-14.
8. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003, 93:96-105.
9. Massberg S, Sausbier M, Klatt P, Bauer M, Pfeifer A, Siess W, Fässler R, Ruth P, Krombach F, Hofmann F. Increased adhesion and aggregation of platelets lacking cyclic guanosine 3',5'-monophosphate kinase I. J Exp Med 1999, 189:1255-64.
10. Walter U, Gambaryan S. Roles of cGMP/cGMP-dependent protein kinase in platelet activation. Blood 2004, 104:2609.
11. Brown GC, Cooper CE. Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal cytochrome oxidase respiration by competing with oxygen at cytochrome oxidase. FEBS Lett 1994, 356:295-8.
12. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006, 97:1676-89.
13. Ahern GP, Klyachko VA, Jackson MB. cGMP S-nitrosylation: two routes for modulation of neuronal excitability by NO. Trends Neurosci 2002, 25:510-7.
14. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G. Species- and tissue-dependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol A Mol Integr Physiol 2005, 142:136-43.
15. Wanstall JC, Homer KL, Doggrell SA. Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol 2005, 3:41-53.
16. Crane MS, Rossi AG, Megson IL. A potential role for extracellular nitric oxide generation in cGMP-independent inhibition of human platelet aggregation: biochemical and pharmacological considerations. Br J Pharmacol 2005, 144:849-59.
17. Sogo N, Magid KS, Shaw CA, Webb DJ, Megson IL. Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun 2000, 279:412-9.
18. Marcondes S, Cardoso MH, Morganti RP, Thomazzi SM, Lilla S, Murad F, De NucciG, Antunes E. Cyclic GMP-independent mechanisms contribute to the inhibition of platelet adhesion by nitric oxide donor: a role for alpha-actinin nitration. Proc Natl Acad Sci USA 2006, 103:3434-9.
19. Oberprieler NG, Roberts W, Riba R, Graham AM, Homer-Vanniasinkam S, Naseem KM. cGMP-independent inhibition of integrin alphaIIbbeta3-mediated platelet adhesion and outside-in signalling by nitric oxide. FEBS Lett 2007, 581:1529-34.
20. Friebe A, Mergia E, Dangel O, Lange A, Koesling D. Fatal gastrointestinal obstruction and hypertension in mice lacking nitric oxide-sensitive guanylyl cyclase. Proc Natl Acad Sci USA 2007, 104:7699-704.
21. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, Koesling D. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 1998, 54:962-7.
22. Mullershausen FM, Russwurm M, Thompson WJ, Liu L, Koesling D, Friebe A. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol 2001, 155:271-8.
23. Halbrugge M, Walter U. Purification of a vasodilator-regulated phosphoprotein from human platelets. Eur J Biochem 1989, 185:41-50.
24. Bellavite P, Andrioli G, Guzzo P, Arigliano P, Chirumbolo S, Manzato F, Santonastaso C. A colorimetric method for the measurement of platelet adhesion in microtiter plates. Anal Biochem 1994, 216:444-50.
25. Morrell CN, Matsushita K, Chiles K, Scharpf RB, Yamakuchi M, Mason RJ, Bergmeier W, Mankowski JL, Baldwin WM, Faraday N, Lowenstein CJ. Regulation of platelet granule exocytosis by S-nitrosylation. Proc Natl Acad Sci USA 2005, 102:3782-7.
26. Geiger J. Inhibitors of platelet signal transduction as anti-aggregatory drugs. Expert Opin Investig Drugs 2001, 10:865-90.
27. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem 2005, 280:1-4.
28. Schwarz UR, Walter U, Eigenthaler M. Taming platelets with cyclic nucleotides. Biochem Pharmacol 2001, 62:1153-61.
29. Halbrugge M, Friedrich C, Eigenthaler M, Schanzenbacher P, Walter U. Stoichiometric and reversible phosphorylation of a 46-kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators. J Biol Chem 1990, 265:3088-93.
30. Gordge MP, Hothersall JS, Noronha-Dutra AA. Evidence for a cyclic GMP-independent mechanism in the anti-platelet action of S-nitrosoglutathione. Br J Pharmacol 1998, 124:141-8.
31. Moro MA, Russel RJ, Cellek S, Lizasoain I, Su Y, Darley-Usmar VM, Radomski MW, Moncada S. cGMP mediates the vascular platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996, 93:1480-5.
32. Schrammel A, Behrends S, Schmidt K, Koesling D, Mayer B. Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a haeme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 1996, 50:1-5.
33. Mullershausen F, Lange A, Mergia E, Friebe A, Koesling D. Desensitization of NO/cGMP signaling in smooth muscle: blood vessels versus airways. Mol Pharmacol 2006, 69:1969-74.
34. Mergia E, Friebe A, Dangel O, Russwurm M, Koesling D. Spare guanylyl cyclase NO receptors ensure high NO sensitivity in the vascular system. J Clin Invest 2006, 116:1731-7.
35. Antl M, von Brühl ML, Eiglsperger C, Werner M, Konrad I, Kocher T, Wilm M, Hofmann F, Massberg S, Schlossmann J. IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation and thrombus formation. Blood 2007, 109:552-9.
36. Hauser W, Knobeloch KP, Eigenthaler M, Gambaryan S, Krenn V, Geiger J, Glazova M, Rohde E, Horak I, Walter U, Zimmer M. Megakaryocyte hyperplasia and enhanced agonist-induced platelet activation in vasodilator-stimulated phosphoprotein knockout mice. Proc Natl Acad Sci USA 1999, 96:8120-5.
37. Aszódi A, Pfeifer A, Ahmad M, Glauner M, Zhou XH, Ny L, Andersson KE, Kehrel B, Offermanns S, Fässler R. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. EMBO J 1999, 18:37-48.